表紙
市場調査レポート

心房細動:世界薬剤予測および市場分析

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 329462
出版日 ページ情報 英文 406 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
心房細動:世界薬剤予測および市場分析 PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2023
出版日: 2015年02月27日 ページ情報: 英文 406 Pages
概要

心房細動は最も一般的な心不整脈であり、様々な治療法があります。2010年以降、新たな経口抗凝固薬が初めて上市されたことで、心房細動患者の治療に変化が起こっています。同薬は抗凝固を大きく進歩させ、今後10年の心房細動市場の成長を牽引することが見込まれています。

当レポートでは、心房細動の概要と治療法、市場収益と予測、パイプライン分析、現在および将来の競合動向、各国別動向、参入企業のプロファイルなどをまとめています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因と病態生理学
  • 症状
  • 心房細動の分類
  • 予後

第4章 疫学

  • 疾患の背景
  • リスクファクターと併存疾患
  • 世界の動向
  • 予測方法
  • 心房細動の疫学的予測
  • ディスカッション

第5章 疾患管理

  • 診断と治療概要
    • 診断
    • 治療ガイドラインと主な処方薬
    • 臨床の現状
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • カナダ

第6章 競合評価

  • 概要
  • 製品プロファイル:抗凝固薬主要ブランド
  • 製品プロファイル:抗不整脈薬主要ブランド
  • その他の治療クラス

第7章 アンメットニーズと機会

  • 概要
  • 洞律動維持のための安全な抗不整脈薬
  • 効果的かつ即時効果のある除細動薬
  • 新経口抗凝固薬の解毒剤
  • 新経口抗凝固薬へのアクセス改善と償還
  • 新経口抗凝固薬の臨床的利点に関する医師への教育充実
  • 新経口抗凝固薬の臨床的利点に関する患者の意識向上

第8章 パイプライン評価

  • 概要
  • 治験マッピング
  • 臨床開発における有望薬剤
  • その他の開発中薬剤

第9章 現在および将来の参入企業

  • 概要
  • 企業戦略動向
  • 企業プロファイル
    • Boehringer Ingelheim
    • Bayer
    • Janssen (Johnson & Johnson)
    • Bristol-Myers Squibb
    • Pfizer
    • 第一三共株式会社
    • Gilead

第10章 市場見通し

  • 世界市場
    • 予測
    • 促進因子と障壁:世界的課題
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • カナダ

第11章 付録

図表

目次
Product Code: GDHC87PIDR

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregular and often abnormally fast heart rate. Various therapeutic options are available to treat patients with AF, and most patients will receive some form of antithrombotic therapy, a heart rate control agent, and potentially, an antiarrhythmic drug for rhythm control.

All sectors of the AF market have historically been saturated with generics, with the vitamin K antagonists such as warfarin playing an important role in stroke prevention in AF. However, since 2010, and the launch of the first of the new oral anticoagulants (NOACs), a shift in the treatment of patients with AF has occurred. The NOACs offer a significant advancement in anticoagulation and their continued uptake will be the main driver of growth in the AF market over the next 10 years.

In contrast, despite a great unmet need for safer antiarrhythmic drugs, developments in this field are expected to be much slower. Two potential antiarrhythmic drugs are in late-stage development and are forecast to enter the market within the next decade: Gilead's ranolazine/dronedarone and ChanRx's vanoxerine.

Highlights

Key Questions Answered

  • The anticoagulant market for stroke prevention in AF has become increasingly crowded. How will the drug treatment landscape for AF change? Which of the NOACs will become the market leader over the next ten years? What are the key drivers and barriers to this change?
  • The AF market is marked by the presence of a number of unmet needs. What are the main unmet needs in the treatment of AF? Will the drugs under development fulfil the unmet needs of the AF market?
  • Will any of the late-stage antiarrhythmic drugs make a significant impact on the AF market? Which of these drugs will have the highest peak sales at the end of the forecast period, and why?

Key Findings

  • The major driver for the growth of the AF market will be the continued uptake of the NOACs for the prevention of stroke in patients with AF. Due to the advances that the NOACs provide in terms of improved safety and the lack of a need for routine monitoring, NOAC uptake will continue to increase, taking market share away from vitamin K antagonists, such as warfarin.
  • The second major driver will be the approval and launch of the first antidotes for the NOACs, which will alleviate physician and patient concerns regarding a lack of a reversal agent in the event of uncontrolled bleeding, and will increase overall uptake.
  • Despite a great unmet need for safer antiarrhythmic drugs, developments in this field are expected to be much slower due to the high risk involved in developing these drugs. Barriers to growth include the requirement for large, costly, and comprehensive clinical trials to support regulatory approval of cardiovascular drugs, which will deter drug developers wanting to enter the AF market. Widely available generic antiarrhythmic drugs will also make it difficult for any novel rhythm control agents to gain reimbursement and wider uptake.

Scope

  • Overview of AF, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized AF therapeutics market revenue, annual cost of therapy, and treatment usage pattern data from 2013, forecast for ten years to 2023.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the AF therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global AF therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global AF therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AF therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global AF therapeutics market from 2013-2023.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Classification of Atrial Fibrillation
  • 3.4. Prognosis

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiological Forecast for Atrial Fibrillation (2013-2023)
    • 4.5.1. Diagnosed Prevalent Cases of Atrial Fibrillation
    • 4.5.2. Age-Specific Diagnosed Prevalent Cases of Atrial Fibrillation
    • 4.5.3. Sex-Specific Diagnosed Prevalent Cases of Atrial Fibrillation
    • 4.5.4. Age-Standardized Diagnosed Prevalence of Atrial Fibrillation
    • 4.5.5. Diagnosed Prevalent Cases of Atrial Fibrillation by Clinical Subtypes
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. France
  • 5.4. Germany
  • 5.5. Italy
  • 5.6. Spain
  • 5.7. UK
  • 5.8. Japan
  • 5.9. Canada

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands, Anticoagulant Agents
    • 6.2.1. Warfarin (Widely Genericized)
    • 6.2.2. Pradaxa (dabigatran)
    • 6.2.3. Xarelto (rivaroxaban)
    • 6.2.4. Eliquis (apixaban)
    • 6.2.5. Savaysa (edoxaban)
  • 6.3. Product Profiles - Major Brands, Antiarrhythmic Drugs
    • 6.3.1. Multaq (dronedarone)
    • 6.3.2. Brinavess (vernakalant)
  • 6.4. Other Therapeutic Classes
    • 6.4.1. Vitamin K Antagonists Other than Warfarin (Widely Genericized)
    • 6.4.2. Antiplatelets - Aspirin (Widely Genericized)
    • 6.4.3. Beta-Blockers - Atenolol, Metoprolol, Propranolol (Widely Genericized)
    • 6.4.4. Calcium Channel Blockers - Diltiazem, Verapamil (Widely Genericized)
    • 6.4.5. Cardiac Glycosides - Digoxin (Widely Genericized)
    • 6.4.6. Potassium Channel Blockers - Amiodarone, Sotalol, Dofetilide (Widely Genericized)
    • 6.4.7. Sodium Channel Blockers - Flecainide, Propafenone (Widely Genericized)

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Safer Antiarrhythmic Drugs for the Maintenance of Sinus Rhythm
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Effective and Rapid Acting Cardioversion Drugs
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Antidotes for the New Oral Anticoagulants
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Improved Access to and Reimbursement of the New Oral Anticoagulants
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Increased Physician Education on the Clinical Benefits of the NOACs
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Increased Patient Awareness on the Clinical Benefits of the NOACs
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Country
    • 8.2.2. Clinical Trials by Phase and Trial Status
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Ranolazine/Dronedarone
    • 8.3.2. Vanoxerine
  • 8.4. Other Drugs in Development
    • 8.4.1. Early-Stage Anticoagulant Pipeline
    • 8.4.2. Early-Stage Antiarrhythmia Pipeline

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Boehringer Ingelheim
    • 9.3.2. Bayer
    • 9.3.3. Janssen (Johnson & Johnson)
    • 9.3.4. Bristol-Myers Squibb
    • 9.3.5. Pfizer
    • 9.3.6. Daiichi-Sankyo
    • 9.3.7. Gilead

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. United Kingdom
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. Canada
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Atrial Fibrillation Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in this Study
  • 11.6. About the Authors
    • 11.6.1. Analyst
    • 11.6.2. Therapy Area Director
    • 11.6.3. Epidemiologist
    • 11.6.4. Global Head of Healthcare
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: Common Cardiac and Non-Cardiac Causes of AF
  • Table 2: Classification of AF
  • Table 3: Clinical Subtypes of AF
  • Table 4: Risk Factors and Comorbidities for AF
  • Table 5: Diagnosed Prevalence (%) of AF in the 6MM,* as Reported in Epidemiological Studies
  • Table 6: Total Prevalence (%) of AF in the 7MM,* as Reported in Epidemiological Studies
  • Table 7: 8MM, Sources of Prevalence Data Used to Forecast the Diagnosed Prevalent Cases of AF
  • Table 8: 8MM, Sources of AF Subtype Data Used to Forecast the Diagnosed Prevalent Cases of AF by Subtypes
  • Table 9: 8MM, Diagnosed Prevalent Cases of AF, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Table 10: 8MM, Diagnosed Prevalent Cases of AF, by Age, Both Sexes, N (Row %), 2013
  • Table 11: 8MM, Diagnosed Prevalent Cases of AF, by Sex, Ages ≥40 Years, N (Row %), 2013
  • Table 12: 8MM, Diagnosed Prevalent Cases of AF, by Clinical Subtypes, Both Sexes, N (Row %), 2013
  • Table 13: CHADS2 Index for Stroke Risk Assessment
  • Table 14: CHA2DS2-VASc Index for Stroke Risk Assessment
  • Table 15: Treatment Guidelines for Atrial Fibrillation by Country
  • Table 16: Most Prescribed Drugs or Drug Classes for AF by Country, 2014
  • Table 17: Country Profile - US
  • Table 18: Country Profile - France
  • Table 19: Country Profile - Germany
  • Table 20: Country Profile - Italy
  • Table 21: Country Profile - Spain
  • Table 22: Country Profile - UK
  • Table 23: Country Profile - Japan
  • Table 24: Country Profile - Canada
  • Table 25: Leading Treatments and Branded Drugs for AF, 2014
  • Table 26: Product Profile - Warfarin (Widely Genericized)
  • Table 27: Warfarin (Widely Genericized) SWOT Analysis, 2014
  • Table 28: Global Sales Forecasts ($m) for Warfarin, 2013-2023
  • Table 29: Product Profile - Pradaxa (dabigatran)
  • Table 30: Pradaxa (dabigatran) SWOT Analysis, 2014
  • Table 31: Global Sales Forecasts ($m) for Pradaxa, 2013-2023
  • Table 32: Product Profile - Xarelto (rivaroxaban)
  • Table 33: Xarelto (rivaroxaban) SWOT Analysis, 2013
  • Table 34: Global Sales Forecasts ($m) for Xarelto, 2013-2023
  • Table 35: Product Profile - Eliquis (apixaban)
  • Table 36: Eliquis (apixaban) SWOT Analysis, 2014
  • Table 37: Global Sales Forecasts ($m) for Eliquis, 2013-2023
  • Table 38: Product Profile - Savaysa (edoxaban)
  • Table 39: Savaysa (edoxaban) SWOT Analysis, 2014
  • Table 40: Global Sales Forecasts ($m) for Savaysa, 2013-2023
  • Table 41: Product Profile - Multaq (dronedarone)
  • Table 42: Overview of the Pivotal Clinical Trials for Multaq
  • Table 43: Efficacy of Multaq in Patients with Paroxysmal or Persistent AF/AFL in the ATHENA Study
  • Table 44: Efficacy of Multaq in Patients with Permanent AF in the PALLAS Study
  • Table 45: Multaq (dronedarone) SWOT Analysis, 2014
  • Table 46: Global Sales Forecasts ($m) for Multaq, 2013-2023
  • Table 47: Product Profile - Brinavess (vernakalant)
  • Table 48: Efficacy of Intravenous Brinavess in Pivotal Late-Stage Clinical Trials
  • Table 49: Brinavess (vernakalant) SWOT Analysis, 2014
  • Table 50: Global Sales Forecasts ($m) for Brinavess, 2013-2023
  • Table 51: Summary of Widely Genericized Therapeutic Classes, 2014
  • Table 52: Commonly Used Genericized Vitamin K Antagonists (Excluding Warfarin), by Region*
  • Table 53: Unmet Need and Opportunity in Atrial Fibrillation
  • Table 54: AF - Clinical Trials by Phase and Status, 2014
  • Table 55: Late-Stage Pipeline for AF, 2014
  • Table 56: Therapeutic Classes in Late-Stage Development for AF, 2014
  • Table 57: Product Profile - Ranolazine/Dronedarone
  • Table 58: Ranolazine/Dronedarone SWOT Analysis, 2014
  • Table 59: Global Sales Forecasts ($m) for Ranolazine/Dronedarone, 2013-2023
  • Table 60: Product Profile - Vanoxerine
  • Table 61: Efficacy of Vanoxerine in Patients with AF/AFL in the Phase IIb COR-ART Study
  • Table 62: Safety of Vanoxerine in Patients with AF/AFL in the Phase IIb COR-ART Study
  • Table 63: Vanoxerine SWOT Analysis, 2014
  • Table 64: Global Sales Forecasts ($m) for Vanoxerine, 2013-2023
  • Table 65: Early-Stage Pipeline Products for Atrial Fibrillation - Anticoagulant Agents
  • Table 66: Early-Stage Pipeline Products for Atrial Fibrillation - Antiarrhythmic Drugs
  • Table 67: Key Companies in the AF Market, 2014
  • Table 68: Boehringer Ingelheim's AF Portfolio Assessment, 2014
  • Table 69: Boehringer Ingelheim SWOT Analysis, 2014
  • Table 70: Bayer's AF Portfolio Assessment, 2014
  • Table 71: Bayer SWOT Analysis, 2014
  • Table 72: Janssen's AF Portfolio Assessment, 2014
  • Table 73: Janssen SWOT Analysis, 2014
  • Table 74: Bristol-Myers Squibb's AF Portfolio Assessment, 2014
  • Table 75: Bristol-Myers Squibb SWOT Analysis, 2014
  • Table 76: Pfizer's AF Portfolio Assessment, 2014
  • Table 77: Pfizer SWOT Analysis, 2014
  • Table 78: Daiichi-Sankyo's AF Portfolio Assessment, 2014
  • Table 79: Daiichi-Sankyo SWOT Analysis, 2014
  • Table 80: Gilead's AF Portfolio Assessment, 2014
  • Table 81: Gilead SWOT Analysis, 2014
  • Table 82: Global* Sales Forecasts ($m) for AF, 2013-2023
  • Table 83: Global AF Market - Drivers and Barriers, 2014
  • Table 84: Sales Forecasts ($m) for AF in the US, 2013-2023
  • Table 85: Key Events Impacting Sales for AF in the US, 2014
  • Table 86: AF Market - Drivers and Barriers in the US, 2013-2023
  • Table 87: Sales Forecasts ($m) for AF in France, 2013-2023
  • Table 88: Key Events Impacting Sales for AF in France, 2014
  • Table 89: AF Market - Drivers and Barriers in France, 2013-2023
  • Table 90: Sales Forecasts ($m) for AF in Germany, 2013-2023
  • Table 91: Key Events Impacting Sales for AF in Germany, 2014
  • Table 92: AF Market - Drivers and Barriers in Germany, 2013-2023
  • Table 93: Sales Forecasts ($m) for AF in Italy, 2013-2023
  • Table 94: Key Events Impacting Sales for AF in Italy, 2014
  • Table 95: AF Market - Drivers and Barriers in Italy, 2013-2023
  • Table 96: Sales Forecasts ($m) for AF in Spain, 2013-2023
  • Table 97: Key Events Impacting Sales for AF in Spain, 2014
  • Table 98: AF Market - Drivers and Barriers in Spain, 2013-2023
  • Table 99: Sales Forecasts ($m) for AF in UK, 2013-2023
  • Table 100: Key Events Impacting Sales for AF in the UK, 2014
  • Table 101: Asthma Market - Drivers and Barriers in the UK, 2013-2023
  • Table 102: Sales Forecasts ($m) for AF in Japan, 2013-2023
  • Table 103: Key Events Impacting Sales for AF in Japan, 2014
  • Table 104: AF Market - Drivers and Barriers in Japan, 2013-2023
  • Table 105: Sales Forecasts ($m) for AF in Canada, 2013-2023
  • Table 106: Key Events Impacting Sales for AF in Canada, 2014
  • Table 107: AF Market - Drivers and Barriers in Canada, 2013-2023
  • Table 108: Key Launch Dates
  • Table 109: Key Patent Expiries
  • Table 110: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: 8MM, Diagnosed Prevalent Cases of AF, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Figure 2: 8MM, Diagnosed Prevalent Cases of AF, by Age, Both Sexes, N, 2013
  • Figure 3: 8MM, Diagnosed Prevalent Cases of AF, by Sex, Ages ≥40 Years, N, 2013
  • Figure 4: 8MM, Age-Standardized Diagnosed Prevalence (%) of AF, by Sex, Ages ≥40 Years, 2013
  • Figure 5: 8MM, Diagnosed Prevalent Cases of AF, by Clinical Subtypes, Both Sexes, N, 2013
  • Figure 6: ESC Guideline Recommendations for Choosing an Anticoagulant
  • Figure 7: JCS Guideline Recommendations for Choosing an Anticoagulant
  • Figure 8: CCS Guideline Recommendations for Choosing an Anticoagulant
  • Figure 9: AHA Guideline Recommendations for Drug Therapy for Ventricular Rate Control
  • Figure 10: AHA Guideline Recommendations for Rhythm Control in Patients with Paroxysmal and Persistent AF
  • Figure 11: ESC Guideline Recommendations for Rhythm Control According to Underlying Pathology
  • Figure 12: JCS Guideline Recommendations for Rhythm Control
  • Figure 13: Site of Action of the New Oral Anticoagulants in the Anticoagulation Cascade
  • Figure 14: AF Therapeutics - Clinical Trials by Country, 2014
  • Figure 15: Competitive Assessment of Late-Stage Pipeline Agents for AF, 2013-2023
  • Figure 16: Company Portfolio Gap Analysis in AF, 2013-2023
  • Figure 17: Global Sales for AF by Country, 2013-2023
  • Figure 18: Annual Global Sales for AF by Region, 2013-2023
  • Figure 19: Global* AF Sales by Drug Class, 2013-2023
  • Figure 20: Annual Global* Sales for AF by Drug Class, 2013-2023
  • Figure 21: Annual Global* Sales for the Novel Oral Anticoagulants, 2013-2023
  • Figure 22: Sales for AF in the US by Drug Class, 2013-2023
  • Figure 23: Sales for AF in France by Drug Class, 2013-2023
  • Figure 24: Sales for AF in Germany by Drug Class, 2013-2023
  • Figure 25: Sales for AF in Italy by Drug Class, 2013-2023
  • Figure 26: Sales for AF in Spain by Drug Class, 2013-2023
  • Figure 27: Sales for AF in the UK by Drug Class, 2013-2023
  • Figure 28: Sales for AF in Japan by Drug Class, 2013-2023
  • Figure 29: Sales for AF in Canada by Drug Class, 2013-2023
Back to Top